Stage III Gallbladder Cancer AJCC v8: Clinical Trials

7 trials for Stage III Gallbladder Cancer AJCC v8, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 2 completed, 1 recruiting, 1 withdrawn. 5 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Active not recruiting 3, Completed 1, Recruiting 1
Phase 33Active not recruiting 1, Completed 1, Withdrawn 1
Phase 11Active not recruiting 1

Follow Stage III Gallbladder Cancer AJCC v8: new trials by email Literature Review of Stage III Gallbladder Cancer AJCC v8 trials Research Report on Stage III Gallbladder Cancer AJCC v8

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Phase 2RecruitingOhio State University Comprehensive Cancer Center292026-11-012026-09-10
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)172024-02-092026-10-19
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
Cisplatin, Gemcitabine Hydrochloride, Lymphadenectomy - Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8
Phase 2 / Phase 3Active not recruitingECOG-ACRIN Cancer Research Group1862021-02-242026-10-19
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)1032020-04-072026-10-02
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma
Phase 2CompletedMayo Clinic282019-10-182023-08-09
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Capecitabine, Cisplatin, Gemcitabine - Stage I Gallbladder Cancer AJCC v8, Stage II Gallbladder Cancer AJCC v8
Phase 3WithdrawnEmory University2019-04-032020-06-05
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8
Phase 3CompletedSWOG Cancer Research Network4522019-02-072026-01-12

Narrower conditions

Gallbladder Neoplasms (7)  ·  Cholangiocarcinoma (4)  ·  Bile Duct Neoplasms (1)  ·  Klatskin Tumor (1)  ·  Neoplasm Metastasis (1)

Broader conditions

Biliary Tract Diseases (7)  ·  Biliary Tract Neoplasms (7)  ·  Digestive System Diseases (7)  ·  Digestive System Neoplasms (7)  ·  Gallbladder Diseases (7)  ·  Neoplasms (7)  ·  Neoplasms by Site (7)  ·  Adenocarcinoma (4)  ·  Carcinoma (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Bile Duct Diseases (1)  ·  Neoplastic Processes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Cisplatin (4)  ·  Gemcitabine (4)  ·  1,2-diaminocyclohexaneplatinum II citrate (3)  ·  Platinum (3)  ·  Specimen Handling (3)  ·  Biopsy (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Capecitabine (1)  ·  Disulfides (1)  ·  Fluorouracil (1)  ·  Immunoglobulin G (1)  ·  Irinotecan (1)  ·  Leucovorin (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Emory University (1)  ·  Mayo Clinic (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  SWOG Cancer Research Network (1)

Countries

United States (7)

Top investigators

Amit Mahipal (1)  ·  Ardaman Shergill (1)  ·  Kristen R Spencer (1)  ·  Rachna Shroff (1)  ·  Sameek Roychowdhury, MD, PhD (1)  ·  Shishir K Maithel (1)  ·  Shishir K. Maithel, MD (1)

Results publications

PMID 37339254, PMID 39671534

NIH funding

U10CA180820 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186716 (1)